Asunto(s)
Corticoesteroides/administración & dosificación , Antiasmáticos/administración & dosificación , Asma/tratamiento farmacológico , Expresión Génica/efectos de los fármacos , Mucosa Nasal/efectos de los fármacos , Administración por Inhalación , Adulto , Beclometasona/administración & dosificación , Budesonida/administración & dosificación , Femenino , Humanos , Masculino , Persona de Mediana EdadRESUMEN
BACKGROUND: Bronchial provocation is often used to confirm asthma. Dyspnea sensation, however, associates poorly with the evoked drop in FEV1. Provocation tests only use the large airways parameter FEV1, although dyspnea is associated with both large- and small airways dysfunction. Aim of this study was to explore if adenosine 5'-monophosphate (AMP) and adenosine evoke an equal dyspnea sensation and if dyspnea associates better with large or small airways dysfunction. METHODS: We targeted large airways with AMP and small airways with dry powder adenosine in 59 asthmatic (ex)-smokers with ≥5 packyears, 14 ± 7 days apart. All subjects performed spirometry, impulse oscillometry (IOS), and Borg dyspnea score. In 36 subjects multiple breath nitrogen washout (MBNW) was additionally performed. We analyzed the association of the change (Δ) in Borg score with the change in large and small airways parameters, using univariate and multivariate linear regression analyses. MBNW was analyzed separately. RESULTS: Provocation with AMP and adenosine evoked similar levels of dyspnea. ΔFEV1 was not significantly associated with ΔBorg after either AMP or adenosine provocation, in both univariate and multivariate analyses. In multivariate linear regression, a decrease in FEF25-75 during adenosine provocation was independently associated with an increase in Borg. In the multivariate analyses for AMP provocation, no significant associations were found between ΔBorg and any large or small airways parameters. CONCLUSION: AMP and adenosine induce equally severe dyspnea sensations. Our results suggest that dyspnea induced with dry powder adenosine is related to small airways involvement, while neither large nor small airways dysfunction was associated with AMP-induced dyspnea. TRAIL REGISTRATION: NCT01741285 at www.clinicaltrials.gov , first registered Dec 4th, 2012.
Asunto(s)
Asma/fisiopatología , Bronquios/efectos de los fármacos , Broncoconstrictores , Disnea/fisiopatología , Adenosina , Adenosina Monofosfato , Adulto , Pruebas de Provocación Bronquial , Disnea/etiología , Femenino , Volumen Espiratorio Forzado/efectos de los fármacos , Humanos , Modelos Lineales , Masculino , Persona de Mediana Edad , Análisis Multivariante , EspirometríaRESUMEN
We performed a post-hoc analysis of the OLiVIA-study investigating whether current and ex-smoking asthmatics with small airways dysfunction (SAD) show a better response in airway hyperresponsiveness (AHR) to small particle adenosine after treatment with extrafine compared to non-extrafine particle inhaled corticosteroids (ICS), and to investigate which clinical parameters predict a favorable response to both treatments. We show that smoking and ex-smoking asthmatics with and without SAD have a similar treatment response with either extrafine or non-extrafine particle ICS. We also found that lower blood neutrophils are associated with a smaller ICS-response in smokers and ex-smokers with asthma, independent from the level of blood eosinophils.
Asunto(s)
Corticoesteroides/administración & dosificación , Antiasmáticos/administración & dosificación , Asma/tratamiento farmacológico , Ex-Fumadores , Tamaño de la Partícula , Fumadores , Fumar/tratamiento farmacológico , Administración por Inhalación , Adulto , Remodelación de las Vías Aéreas (Respiratorias)/efectos de los fármacos , Remodelación de las Vías Aéreas (Respiratorias)/fisiología , Asma/sangre , Asma/diagnóstico , Eosinófilos/efectos de los fármacos , Eosinófilos/metabolismo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Valor Predictivo de las Pruebas , Fumar/sangre , Resultado del TratamientoAsunto(s)
Adenosina Monofosfato/administración & dosificación , Adenosina/administración & dosificación , Asma/diagnóstico , Pruebas de Provocación Bronquial/métodos , Broncoconstrictores/administración & dosificación , Adulto , Hiperreactividad Bronquial/diagnóstico , Inhaladores de Polvo Seco , Femenino , Volumen Espiratorio Forzado , Humanos , Modelos Lineales , Masculino , Persona de Mediana Edad , Análisis MultivarianteRESUMEN
BACKGROUND: Smoking is as prevalent in asthmatics as in the general population. Asthmatic smokers benefit less from inhaled corticosteroids (ICS) than non-smoking asthmatics, possibly due to more smoking-induced small airways disease. Thus targeting small airways may be important in treating asthmatic (ex-)smokers. We hypothesized that extrafine particle ICS improve small airways function more than non-extrafine particle ICS in asthmatic (ex-)smokers. METHODS: We performed an open-label, randomized, three-way cross-over study comparing extrafine beclomethasone (HFA-QVAR) to non-extrafine beclomethasone (HFA-Clenil) and fluticasone (HFA-Flixotide) in 22 smokers and 21 ex-smokers with asthma (?5 packyears). RESULTS: Improvement from baseline in PD20 adenosine after using QVAR, Clenil or Flixotide was 1.04 ± 1.71, 1.09 ± 2.12 and 0.94 ± 1.97 doubling doses, mean ± standard deviation (SD), respectively. The change from baseline in R5-R20 at PD20 adenosine after using QVAR, Clenil or Flixotide was ?0.02 ± 0.27, 0.02 ± 0.21, and ?0.02 ± 0.31 kPa sL?1, mean ± SD, respectively. The change in PD20 adenosine and R5-R20 at PD20 adenosine were neither statistically significant different between QVAR and Clenil (p = 0.86 and p = 0.82) nor between QVAR and Flixotide (p = 0.50 and p = 0.96). CONCLUSION: Similar effectiveness in improving small airways function was found for extrafine and non-extrafine particle ICS treatment for asthmatic smokers and ex-smokers.
Asunto(s)
Corticoesteroides/uso terapéutico , Remodelación de las Vías Aéreas (Respiratorias)/efectos de los fármacos , Asma/tratamiento farmacológico , Beclometasona/uso terapéutico , Fumadores/estadística & datos numéricos , Adenosina Monofosfato/metabolismo , Administración por Inhalación , Corticoesteroides/administración & dosificación , Adulto , Asma/diagnóstico , Asma/epidemiología , Asma/fisiopatología , Beclometasona/administración & dosificación , Pruebas de Provocación Bronquial/métodos , Estudios Cruzados , Femenino , Fluticasona/administración & dosificación , Fluticasona/uso terapéutico , Volumen Espiratorio Forzado/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Tamaño de la Partícula , Pruebas de Función Respiratoria/métodos , Resultado del TratamientoRESUMEN
OBJECTIVE: To evaluate prescriptions of asthma medication for children in primary care. METHODS: Data on prescriptions of asthma medication for children aged 0-9 years were collected from a general practice-based network in the north eastern part of the Netherlands. Prevalence, incidence, indications, continuation beyond the age of 6 years, and predictors of continuation, were determined. RESULTS: Prevalence of prescriptions was about 80 per 1000 person years. An asthma diagnosis was registered in 40% of the children with a first prescription and in 70% of the children with six or more prescriptions. Discontinuation of asthma medication was between 60 and 90%. Continuation was more likely in children with a first prescription at age 2 or 3 as compared to children starting treatment at age < or =1 year. Children with prescriptions for beta2-agonists and inhaled corticosteroids were more likely to continue treatment than children with beta2-agonist monotherapy prescriptions. CONCLUSION: Continuation of asthma medication in children is low. Age at first prescription and the type of asthma medication are predictors of continuation of asthma medication from preschool into school-age.
Asunto(s)
Antiasmáticos/uso terapéutico , Asma/tratamiento farmacológico , Prescripciones/estadística & datos numéricos , Corticoesteroides/uso terapéutico , Distribución por Edad , Asma/diagnóstico , Asma/epidemiología , Niño , Preescolar , Quimioterapia Combinada/estadística & datos numéricos , Utilización de Medicamentos , Femenino , Humanos , Lactante , Recién Nacido , Estimación de Kaplan-Meier , Estudios Longitudinales , Masculino , Países Bajos/epidemiología , Aceptación de la Atención de Salud , Medicamentos bajo Prescripción/uso terapéutico , Atención Primaria de Salud , Sistema de RegistrosRESUMEN
Chronic obstructive pulmonary disease (COPD) is a prevalent disease, with cigarette smoking being the main risk factor. Prevention is crucial in the fight against COPD. Whereas primary prevention is targeted on whole populations, patient populations are the focus of primary care; therefore, prevention in this setting is mainly aimed at preventing further deterioration of the disease in patients who present with the first signs of disease (secondary prevention). Prevention of COPD in primary care requires detection of COPD at an early stage. An accurate definition of COPD is crucial in this identification process. The benefits of detecting new patients with COPD should be determined before recommending screening and case-finding programs in primary care. No evidence is available that screening by spirometry results in significant health gains. Effective treatment options in patients with mild disease are lacking. Smoking cessation is the cornerstone of COPD prevention. Because cigarette smoking is not only a major cause of COPD but is also a major cause of many other diseases, a decline in tobacco smoking would result in substantial health benefits.
Asunto(s)
Atención Primaria de Salud/métodos , Enfermedad Pulmonar Obstructiva Crónica/prevención & control , Adulto , Anciano , Humanos , Persona de Mediana Edad , Cese del Hábito de FumarRESUMEN
RATIONALE: Beneficial effects of anti-inflammatory therapy such as fluticasone propionate (FP) and montelukast (Mk) have been demonstrated in preschool children with asthma. However, comparative studies are lacking in this age group. Therefore, we conducted a study to evaluate and compare the effect of FP and Mk in preschool children with asthma-like symptoms. METHODS: In this multicenter, randomized, placebo-controlled, double-blind, double-dummy trial, children aged 2-6 years with asthma-like symptoms were included. In total, 63 children were randomly allocated to receive FP (25), Mk (18) or placebo (20) for 3 months. The primary outcome was the daily symptom score (wheeze, cough, shortness of breath) as recorded by caregivers in a symptom diary card. Secondary endpoints were rescue medication free days, blood eosinophils and lung function (interrupter technique and forced oscillation technique (FOT)). RESULTS: During the 3 months study period, symptoms improved in all 3 groups, with a statistically significant difference between FP and placebo in favor of the FP group (p=0.021). A significant reduction in circulating eosinophils after 3 months of treatment was found in the Mk group only (p=0.008), which was significantly different from the change found in the placebo group (p=0.045). With the exception of frequency dependence (measured by FOT), which showed a difference between FP and Mk after 3 months of treatment in favor of the FP group (p=0.048), no differences in lung function within or between groups were found. CONCLUSIONS: In spite of a lack of power, our results suggest that FP has a beneficial effect on symptoms and Mk on blood eosinophil level as compared to placebo. Except for a difference in one lung function parameter after 3 months between FP and Mk in favor of the FP group, this study revealed no differences between FP and Mk.
Asunto(s)
Acetatos/uso terapéutico , Androstadienos/uso terapéutico , Asma/tratamiento farmacológico , Quinolinas/uso terapéutico , Acetatos/administración & dosificación , Administración Oral , Androstadienos/administración & dosificación , Antiasmáticos/administración & dosificación , Antiasmáticos/uso terapéutico , Antiinflamatorios/administración & dosificación , Antiinflamatorios/uso terapéutico , Asma/fisiopatología , Preescolar , Ciclopropanos , Método Doble Ciego , Femenino , Fluticasona , Humanos , Masculino , Inhaladores de Dosis Medida , Países Bajos , Servicio Ambulatorio en Hospital , Quinolinas/administración & dosificación , Pruebas de Función Respiratoria/métodos , Sulfuros , Comprimidos , Factores de Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND: Therapy with inhaled corticosteroids (ICS) is beneficial in patients with asthma. However, in preschool children with symptoms like cough, wheeze, or shortness of breath diagnosing asthma is difficult. Therefore, the role of ICS in the management of preschool children with recurrent respiratory symptoms is unclear. We assessed the effectiveness of ICS in preschool children with recurrent respiratory symptoms in general practice. METHODS: In this multicenter, randomized, double blind, placebo controlled trial, 96 children aged 1-5 years consulting their general practitioners for recurrent respiratory symptoms and in whom treatment with ICS was considered by the general practitioner were randomly allocated to receive ICS (fluticasone propionate 200 mcg/day by metered dose inhaler/spacer combination) or placebo for 6 months. Outcome assessments were carried out 1, 3, and 6 months after randomization. The primary outcome measure was the symptom score (cough, shortness of breath and wheeze during day and night) as measured by a symptom diary card. Secondary endpoints were symptom-free days, use of rescue medication, adverse events, and lung function variables as measured by the interrupter technique and forced oscillation technique. RESULTS: During the 6 months treatment period, symptoms improved in both groups, with no differences between ICS and placebo. In addition, none of the secondary outcome parameters showed differences between both treatment groups. CONCLUSION: ICS treatment has no beneficial effect in preschool children with recurrent respiratory symptoms in general practice. We therefore recommend a watchful waiting policy with only symptomatic treatment in these children. General practitioners and pediatricians should be aware of the high probability of overtreatment when prescribing ICS in these children.
Asunto(s)
Androstadienos/uso terapéutico , Antiinflamatorios/uso terapéutico , Glucocorticoides/uso terapéutico , Trastornos Respiratorios/tratamiento farmacológico , Administración por Inhalación , Androstadienos/administración & dosificación , Androstadienos/efectos adversos , Antiinflamatorios/administración & dosificación , Antiinflamatorios/efectos adversos , Preescolar , Método Doble Ciego , Medicina Familiar y Comunitaria , Femenino , Fluticasona , Glucocorticoides/administración & dosificación , Glucocorticoides/efectos adversos , Humanos , Lactante , Masculino , Inhaladores de Dosis MedidaRESUMEN
BACKGROUND: The new Global Obstructive Lung Disease (GOLD) guidelines advice to focus treatment in Chronic Obstructive Pulmonary Disease (COPD) on improvement of functional state, prevention of disease progression and minimization of symptoms. So far no validated questionnaires are available to measure symptom and functional state in daily clinical practice. The aim of this study was to develop and validate the Clinical COPD Questionnaire (CCQ). METHODS: Qualitative research with patients and clinicians was performed to generate possible items to evaluate clinical COPD control. Thereafter, an item reduction questionnaire was sent to 77 international experts. Sixty-seven experts responded and the 10 most important items, divided into 3 domains (symptoms, functional and mental state) were included in the CCQ (scale: 0 = best, 6 = worst). RESULTS: Cross-sectional data were collected from 119 subjects (57 COPD, GOLD stage I-III; 18 GOLD stage 0 and 44 (ex)smokers). Cronbach's alpha was high (0.91). The CCQ scores in patients (GOLD 0-III) were significantly higher than in healthy (ex)smokers. Furthermore, significant correlations were found between the CCQ total score and domains of the SF-36 (rho = 0.48 to rho = 0.69) and the SGRQ (rho = 0.67 to rho = 0.72). In patients with COPD, the correlation between the CCQ and FEV1%pred was rho =-0.49. Test-retest reliability was determined in 20 subjects in a 2-week interval (Intra Class Coefficient = 0.94). Thirty-six smokers with and without COPD showed significant improvement in the CCQ after 2 months smoking cessation, indicating the responsiveness of the CCQ. CONCLUSION: The CCQ is a self-administered questionnaire specially developed to measure clinical control in patients with COPD. Data support the validity, reliability and responsiveness of this short and easy to administer questionnaire.
Asunto(s)
Enfermedad Pulmonar Obstructiva Crónica/clasificación , Perfil de Impacto de Enfermedad , Encuestas y Cuestionarios , Actividades Cotidianas , Adulto , Anciano , Estudios Transversales , Femenino , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Países Bajos , Calidad de Vida , Reproducibilidad de los Resultados , Índice de Severidad de la EnfermedadRESUMEN
OBJECTIVE: To evaluate the effectiveness of inhaled corticosteroid therapy in asthmatic children in the age group of 0-6 years. STUDY DESIGN: Systematic review of randomised double blind placebo controlled trials of inhaled corticosteroid therapy for preschool children with asthma. 12 Trials were identified for this review. Data on symptom scores, parents' sleep disturbance, parents' assessment of asthma status/medication, concomitant drug use, exacerbation rate, lung function measurement, and adverse effects were retrieved form the trials. RESULTS: Most parallel trials showed significant improvements in symptom scores, concomitant drug use, exacerbation rate, or lung function measurements. Most improvements were seen in wheeze and concomitant drug use. The pooled odds ratio (95% confidence interval (CI)) for outcome measure 'patients with at least one exacerbation' was 0.47 (0.3 to 0.73). Two crossover trials showed significant improvements in symptom scores, ß-agonist use, and lung function. Significant differences in adverse effects between the active and placebo groups were not detected. CONCLUSION: In conclusion, this systematic review of literature shows beneficial effects on symptoms, exacerbation rate, and pulmonary function for the use of inhaled corticosteroids in preschool children with asthma.